Paul A Mahon

Paul A Mahon (EVP & General Counsel) sold 8,300 shares for $4,494,840.77 on 2026-06-18 via scheduled 10b5-1 plan

Paul A Mahon executed 11 separate sales totaling 8,300 shares for $4,494,840.77 on 2026-06-18 at prices ranging from $537.04 to $548.91, with a blended average price of $541.55. This transaction is part of a pre-arranged 10b5-1 trading plan, so it reflects scheduled execution rather than discretionary timing. Post-transaction, Mahon retains 45,172 shares of non-derivative holdings, a -15.5% reduction from his pre-transaction position of 53,472 shares; additionally, he maintains 97,340 shares in stock options. The company's fundamentals remain solid, with latest-quarter revenue of $781,500,000.00, net income of $274,900,000.00, and annual revenue growth of +10.6%, yielding a P/E of 17.69 and market cap of $22,776,492,460.47.

EVP & General Counsel Paul A Mahon sold 8,300 shares at avg $547.07 via 8 scheduled transactions, now holds 45,172 shares post-sale.

Paul A Mahon, EVP & General Counsel at United Therapeutics Corp, executed 8 separate sales totaling 8,300 shares for $4,540,642.42 on 2026-06-04 as part of a pre-arranged 10b5-1 trading plan. His post-transaction holdings stand at 45,172 shares, down from 53,472 shares pre-transaction, representing a -15.5% reduction in his non-derivative position; however, he retains 105,640 shares of stock options outstanding. The blended average transaction price of $547.07 sits -9.8% below the 52-week high of $609.35. His cross-ticker track record shows 20 prior sells with an average 90-day return of -5.8%, while his five prior trades specifically at UTHR (all on 2026-05-21) showed 30-day and 90-day returns ranging from -2.8% to -4.1%. Because this sale is scheduled under a 10b5-1 plan rather than discretionary, the timing reflects pre-set execution rather than current market judgment.

Paul A Mahon sells 8,300 shares of UTHR for $4,671,399.11 via 10 transactions on 2026-05-21

Paul A Mahon, EVP & General Counsel, executed 10 separate sales totaling 8,300 shares for $4,671,399.11 on 2026-05-21 under a pre-arranged 10b5-1 trading plan. His post-transaction holding of 45,172 shares represents a -15.5% reduction from the prior 53,472 shares. The stock currently trades at $563.93, near the blended average price of $562.82 at which the sales occurred, within the 52-week range of $272.12–$609.35. His cross-ticker track record shows 20 prior sells with an average 90d return of -1.9%, while his prior UTHR trades (5 sales on 2026-05-07) showed returns ranging from -5.1% to -2.8% at the 30- and 90-day horizons. This sale is mechanically executed under a scheduled plan, not a discretionary choice.

UTHR EVP & General Counsel Paul Mahon exercises options for 8,300 shares while selling 7,300 shares across nine tranches — net addition of ~1,000 shares

Paul Mahon, EVP and General Counsel of United Therapeutics, exercised options to acquire shares and simultaneously sold a nearly equivalent number across nine separate tranches on the same day, resulting in a net increase of roughly one thousand shares to his holdings. United Therapeutics is a profitable company with modest revenue growth, providing a fundamentally stable backdrop for this activity. Mahon has an extensive history of selling in this stock, with his prior same-ticker sales all occurring at prices that proved, in hindsight, to be below where the stock subsequently traded — meaning every one of those earlier exits was poorly timed, as the stock rose after each sale. That said, it is worth noting that the SAME-TICKER HISTORY details five prior sell transactions, while the full insider track record documents twenty prior sells — so the poor timing pattern visible in the detailed history appears consistent with his broader record of exits in this name. The net result of today's exercise-and-sell activity is a modest increase in Mahon's position rather than a meaningful accumulation, limiting the informational signal this filing carries on its own.

EVP & General Counsel Paul A. Mahon sold 8,300 shares for $4,787,596.55 at blended average $576.82 on 2026-04-16.

Paul A. Mahon, EVP & General Counsel of United Therapeutics, executed 5 separate sales totaling 8,300 shares for $4,787,596.55 on 2026-04-16, reducing his holdings from 53,472 shares to 45,172 shares (a -15.5% reduction). The sales occurred at prices ranging from $574.03 to $578.21, with a blended average of $576.82. At the current price of $580.51, the stock is -2.1% from its 52-week high of $592.98 and has appreciated +7.5% over the prior 30 days and +24.9% over the prior 90 days. Mahon's cross-ticker track record shows 20 prior sells with an average 30-day return of +17.2%, though his 5 prior same-ticker sales at UTHR on 2026-04-02 do not yet have measurable 30-day or 90-day outcomes. The company's fundamentals remain solid with FY revenue growth of +10.6%, quarterly net income of $338.7M, and a P/E of 18.03.

EVP & General Counsel Paul Mahon sells 8,300 shares of UTHR for $4.7M at blended average $565.87

Paul A. Mahon, EVP & General Counsel, executed 11 separate sales totaling 8,300 shares for $4,696,690.20 on 2026-04-02, with a blended average price of $565.87. Post-transaction, he retains 45,172 shares (45.2K shares), representing a -15.5% reduction from pre-transaction holdings of 53,472 shares. The stock closed at $564.81 on the filing date, only $1.06 below the blended average transaction price, and is trading -4.8% from its 52-week high of $592.98. While Mahon's cross-ticker track record shows 20 prior sells with an average 30-day return of +10.3%, his same-ticker history at UTHR consists of 5 recent sales on 2026-03-19 with outcomes not yet measurable. The company reports strong fundamentals with revenue of $799,500,000 and net income of $338,700,000, paired with annual revenue growth of +10.6% and a P/E of 17.54, suggesting no obvious operational distress driving the sale.

EVP & General Counsel MAHON PAUL A sold 8,300 shares at blended average $529.95 on 2026-03-19 for $4.4M, reducing holdings to 45,172 shares.

MAHON PAUL A executed 7 separate sales totaling 8,300 shares for $4,398,610.93 ($4.4M) on a single day, with transaction prices ranging from $527.47 to $533.41. The sale reduced his holdings by 15.5% relative to pre-transaction levels. The transactions were executed at prices near the stock's 52-week high of $544.71 (current price $527.00 is -3.2% from that peak), and occurred just 14 days after a cluster of prior sales on 2026-03-05 (outcome measurements pending). United Therapeutics posted strong recent fundamentals: $799.5M quarterly revenue, $338.7M net income, and 10.6% annual revenue growth, with P/E of 16.37. His cross-ticker track record shows 20 prior sells with an average 30-day return of -1.2%, though timing outcomes at this specific ticker are not yet measurable. The concentration of sales in a single-day multi-tranche execution, the timing relative to 52-week highs, and the rapid repeat selling pattern warrant closer examination of broader context.

UTHR EVP/GC Paul Mahon sold 8,300 shares for $4.0M across 9 transactions on 2026-03-05 at blended $483.16

Paul A. Mahon, EVP & General Counsel of United Therapeutics, executed 9 separate sales totaling 8,300 shares for $4,010,187.14 on March 5, 2026, reducing his holdings by 18.4% from 45,144 to 36,844 shares. The blended average price of $483.16 is near current levels ($485.06), and his cross-ticker track record shows an average 30-day return of +0.6% following prior sells, indicating his historical sales have not typically preceded sharp declines. His 5 most recent same-ticker trades at UTHR were all sells on 2026-02-19, outcomes for which are not yet measurable; no timing pattern is available for his UTHR activity. Against a backdrop of solid fundamentals (revenue $799.5M, net income $338.7M, 10.6% annual growth, P/E of 15.06), this multi-transaction liquidation represents a meaningful but not dominant reduction in an executive's position.

UTHR: EVP General Counsel Mahon Paul A sold 8,300 shares in 8 transactions for $3,953,588.22 on 2026-02-19

Paul A Mahon (EVP & General Counsel) executed 8 separate sales totaling 8,300 shares for $3,953,588.22 on 2026-02-19, reducing his holdings from 45,081 shares to 36,781 shares (-18.4%). The blended average transaction price of $476.34 falls slightly below the current price of $480.52, and within the 52-week range of $274.70–$517.13. United Therapeutics reports strong fundamentals with $799.5M in latest-quarter revenue, $338.7M net income, +23.6% annual growth, and a 16.27 P/E, suggesting a company in good operational standing. His cross-ticker track record shows 20 prior sells with an average 30-day return of -1.6%, though prior same-ticker trades at UTHR executed on 2026-02-05 remain too recent to measure. This sale represents a material reduction in position, occurring during a period of moderate stock appreciation (+2.7% in 30 days, +1.2% in 90 days), with no measurable pattern of well-timed exit points established at this ticker to date.

EVP & General Counsel sold 8,300 shares at blended avg $483.25 for $4.0M on 2026-02-05

Paul A. Mahon executed 6 separate sales totaling 8,300 shares for $4,010,939.66, reducing his holdings from 45,081 to 36,781 shares (an 18.4% reduction). The sales occurred at prices ranging from $480.92 to $485.52, slightly above the current price of $478.93 and well within the 52-week range of $274.70–$517.13. The company's financials remain strong with $799.5M quarterly revenue, $338.7M net income, and annual growth of +23.6%, alongside a reasonable P/E of 16.21. His cross-ticker track record shows 20 prior sells with an average 30-day return of -5.4%, though no outcome data is yet available for his 5 recent same-ticker transactions at UTHR (all from 2026-01-15), limiting direct assessment of his timing patterns at this specific stock.